Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Sep;98(38):e17190.
doi: 10.1097/MD.0000000000017190.

The efficacy and safety of long-term add-on treatment of azithromycin in asthma: A systematic review and meta-analysis

Xiaohu Wang  1 , Jian Luo, Dan Wang, Bicui Liu, Chuntao Liu
Affiliations
Meta-Analysis

The efficacy and safety of long-term add-on treatment of azithromycin in asthma: A systematic review and meta-analysis

Xiaohu Wang et al. Medicine (Baltimore). 2019 Sep.

Abstract

Aim: Effects of azithromycin on asthma reported in clinical trials are less consistent. We aimed to further clarify the efficacy and safety of azithromycin in treatment of asthma.

Methods: The protocol registration number was CRD42017074318 (http://www.crd.york.ac.uk/Prospero). We searched PubMed, EMBASE, Cochrane databases, China National Knowledge Internet (CNKI), and Wanfang databases for the randomized controlled trials (RCTs) with prolonged treatment of azithromycin for more than 3 weeks. Random-effects or fixed-effects model was applied to calculate risk ratio (RR) and mean difference (MD) for dichotomous and continuous data respectively.

Results: A total of eight studies were included for analysis. The pooled result of adjunctive azithromycin therapy in asthma showed a small, but statistically significant increase in forced expiratory volume in one second (FEV1) (MD = 0.06, 95% confidence interval [CI]: 0.01-0.12, P = .02), but no significant differences in exacerbation frequency (MD = -0.42, 95%CI: -1.13 to 0.30, P = .25) and peak expiratory flow (PEF) (MD = 0.20, 95% CI: -0.05 to 0.44, P = .12), fractional exhaled nitric oxide (FeNO) (MD = 4.12, 95% CI: -2.06 to 10.30, P = .19), asthma quality of life questionnaire (AQLQ) (MD: 0.05, 95% CI: -0.17 to 0.28, P = .65), asthma control questionnaire (ACQ) (MD: -0.03, 95% CI: -0.21 to 0.15, P = .75). The subgroup analysis revealed that azithromycin could decrease FeNO among Asian asthma (MD = 15.04, 95% CI: 6.18-23.90, P = .0009).

Conclusions: Add-on therapy of azithromycin in asthma patients could improve the FEV1, but failed to improve asthma exacerbations, PEF, ACQ, AQLQ, and FeNO. Subgroup analysis indicated that azithromycin could improve FeNO in Asian group asthmatics.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Competing interests: The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Flow chart of study identification, inclusion, and exclusion.
Figure 2
Figure 2
Risk of bias assessment summary.
Figure 3
Figure 3
Effects of azithromycin on asthma exacerbations.
Figure 4
Figure 4
Effects of azithromycin on FEV1 (L).
Figure 5
Figure 5
Effects of azithromycin on PEF (L/min).
Figure 6
Figure 6
Effects of azithromycin on FeNO (ppb).
Figure 7
Figure 7
Effects of azithromycin on ACQ.
Figure 8
Figure 8
Effects of azithromycin on AQLQ.
Figure 9
Figure 9
Effects of azithromycin on side effects.
See this image and copyright information in PMC

References

    1. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol 2001;107:3–8. - PubMed
    1. Calhoun WJ, Haselkorn T, Mink DR, et al. Clinical burden and predictors of asthma exacerbations in patients on guideline-based steps 4–6 asthma therapy in the TENOR cohort. J Allergy Clin Immunol Pract 2014;2:193–200. - PubMed
    1. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015;3:355–66. - PubMed
    1. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198–207. - PubMed
    1. Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ, et al. Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther 2014;143:225–45. - PubMed

MeSH terms